S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.86 (-1.95%)
AAPL   171.52 (-1.51%)
MSFT   286.15 (-1.39%)
META   167.96 (-3.84%)
GOOGL   117.21 (-2.46%)
AMZN   138.23 (-2.86%)
TSLA   890.00 (-2.05%)
NVDA   178.49 (-4.92%)
NIO   19.05 (-4.32%)
BABA   89.63 (-1.22%)
AMD   95.95 (-4.47%)
T   18.43 (+0.00%)
MU   60.51 (-3.92%)
CGC   3.82 (+0.26%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.14 (-2.06%)
AMC   18.02 (-6.58%)
PYPL   96.56 (-3.30%)
PFE   49.15 (+1.17%)
NFLX   241.16 (-1.64%)
S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.86 (-1.95%)
AAPL   171.52 (-1.51%)
MSFT   286.15 (-1.39%)
META   167.96 (-3.84%)
GOOGL   117.21 (-2.46%)
AMZN   138.23 (-2.86%)
TSLA   890.00 (-2.05%)
NVDA   178.49 (-4.92%)
NIO   19.05 (-4.32%)
BABA   89.63 (-1.22%)
AMD   95.95 (-4.47%)
T   18.43 (+0.00%)
MU   60.51 (-3.92%)
CGC   3.82 (+0.26%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.14 (-2.06%)
AMC   18.02 (-6.58%)
PYPL   96.56 (-3.30%)
PFE   49.15 (+1.17%)
NFLX   241.16 (-1.64%)
S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.86 (-1.95%)
AAPL   171.52 (-1.51%)
MSFT   286.15 (-1.39%)
META   167.96 (-3.84%)
GOOGL   117.21 (-2.46%)
AMZN   138.23 (-2.86%)
TSLA   890.00 (-2.05%)
NVDA   178.49 (-4.92%)
NIO   19.05 (-4.32%)
BABA   89.63 (-1.22%)
AMD   95.95 (-4.47%)
T   18.43 (+0.00%)
MU   60.51 (-3.92%)
CGC   3.82 (+0.26%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.14 (-2.06%)
AMC   18.02 (-6.58%)
PYPL   96.56 (-3.30%)
PFE   49.15 (+1.17%)
NFLX   241.16 (-1.64%)
S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.86 (-1.95%)
AAPL   171.52 (-1.51%)
MSFT   286.15 (-1.39%)
META   167.96 (-3.84%)
GOOGL   117.21 (-2.46%)
AMZN   138.23 (-2.86%)
TSLA   890.00 (-2.05%)
NVDA   178.49 (-4.92%)
NIO   19.05 (-4.32%)
BABA   89.63 (-1.22%)
AMD   95.95 (-4.47%)
T   18.43 (+0.00%)
MU   60.51 (-3.92%)
CGC   3.82 (+0.26%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.14 (-2.06%)
AMC   18.02 (-6.58%)
PYPL   96.56 (-3.30%)
PFE   49.15 (+1.17%)
NFLX   241.16 (-1.64%)
NASDAQ:MYGN

Myriad Genetics - MYGN Stock Forecast, Price & News

$24.86
-0.38 (-1.51%)
(As of 08/19/2022 12:00 AM ET)
Add
Compare
Today's Range
$24.63
$25.06
50-Day Range
$16.45
$27.88
52-Week Range
$16.02
$36.95
Volume
306,321 shs
Average Volume
546,180 shs
Market Capitalization
$2.00 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.33

Myriad Genetics MarketRank™ Forecast

Analyst Rating
Hold
1.50 Rating Score
Upside/​Downside
14.0% Upside
$28.33 Price Target
Short Interest
Healthy
4.74% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.60
Upright™ Environmental Score
News Sentiment
0.69mentions of Myriad Genetics in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$123,662 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.44) to ($0.23) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.03 out of 5 stars

Medical Sector

654th out of 1,116 stocks

Diagnostic Substances Industry

8th out of 16 stocks

MYGN stock logo

About Myriad Genetics (NASDAQ:MYGN) Stock

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

Myriad Genetics Stock Performance

NASDAQ:MYGN traded down $0.46 on Friday, reaching $24.78. The stock had a trading volume of 2,915 shares, compared to its average volume of 552,851. Myriad Genetics has a 1 year low of $16.02 and a 1 year high of $36.95. The business has a 50 day moving average price of $22.02 and a 200 day moving average price of $22.94.

Myriad Genetics (NASDAQ:MYGN - Get Rating) last announced its quarterly earnings results on Thursday, August 4th. The company reported $0.04 EPS for the quarter, beating the consensus estimate of $0.01 by $0.03. Myriad Genetics had a negative return on equity of 3.44% and a negative net margin of 2.62%. The business had revenue of $179.30 million during the quarter, compared to analysts' expectations of $170.05 million. During the same quarter in the previous year, the business posted $0.03 EPS. The firm's quarterly revenue was down 5.3% compared to the same quarter last year. Analysts anticipate that Myriad Genetics will post -0.44 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on MYGN. StockNews.com cut Myriad Genetics from a "buy" rating to a "hold" rating in a research note on Wednesday, July 13th. Cowen boosted their price objective on Myriad Genetics to $32.00 in a report on Tuesday, August 9th. TheStreet cut shares of Myriad Genetics from a "c-" rating to a "d+" rating in a research report on Friday, June 3rd. Finally, SVB Leerink lifted their price target on Myriad Genetics from $26.00 to $30.00 and gave the company a "market perform" rating in a report on Friday, August 5th.

Insider Activity

In other Myriad Genetics news, Director Daniel K. Spiegelman sold 6,424 shares of the stock in a transaction that occurred on Monday, June 6th. The stock was sold at an average price of $19.25, for a total transaction of $123,662.00. Following the transaction, the director now owns 33,980 shares in the company, valued at $654,115. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 1.80% of the stock is currently owned by insiders.

Receive MYGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Myriad Genetics and its competitors with MarketBeat's FREE daily newsletter.

MYGN Stock News Headlines

This Unpopular Move Could Save Invitae
Myriad Genetics, Inc.
Myriad Genetics Earnings Preview
Myriad Genetics Inc
See More Headlines
Receive MYGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Myriad Genetics and its competitors with MarketBeat's FREE daily newsletter.

MYGN Company Calendar

Last Earnings
8/04/2022
Today
8/19/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:MYGN
CUSIP
62855J10
Employees
2,400
Year Founded
1991

Price Target and Rating

Average Stock Price Forecast
$28.33
High Stock Price Forecast
$32.00
Low Stock Price Forecast
$23.00
Forecasted Upside/Downside
+14.0%
Consensus Rating
Hold
Rating Score (0-4)
1.50
Research Coverage
2 Analysts

Profitability

Net Income
$-27,200,000.00
Pretax Margin
-7.14%

Debt

Sales & Book Value

Annual Sales
$690.60 million
Cash Flow
$0.46 per share
Book Value
$11.75 per share

Miscellaneous

Free Float
79,184,000
Market Cap
$2.00 billion
Optionable
Optionable
Beta
1.70

Social Links


Key Executives

  • Mr. Paul J. Diaz (Age 60)
    CEO, Pres & Director
    Comp: $2.92M
  • Mr. R. Bryan Riggsbee (Age 51)
    Exec. VP, CFO & Treasurer
    Comp: $934.49k
  • Ms. Nicole LambertMs. Nicole Lambert (Age 48)
    Chief Operating Officer
    Comp: $825.23k
  • Mr. Mark S. Verratti (Age 54)
    Chief Commercial Officer
    Comp: $723.29k
  • Ms. Natalie Munk (Age 41)
    Principal Accounting Officer
  • Dr. Kevin Richard Haas (Age 36)
    Chief Technology Officer
  • Dr. Dale Muzzey Ph.D. (Age 42)
    Chief Scientific Officer
  • Mr. Scott Gleason (Age 43)
    Sr. VP of Investor Relations
  • Dr. Clivetty Martinez
    Chief Compliance Officer
  • Ms. Pamela Wong (Age 54)
    Chief Legal Officer













MYGN Stock - Frequently Asked Questions

Should I buy or sell Myriad Genetics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Myriad Genetics in the last twelve months. There are currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MYGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MYGN, but not buy additional shares or sell existing shares.
View MYGN analyst ratings
or view top-rated stocks.

What is Myriad Genetics' stock price forecast for 2022?

2 brokerages have issued 12 month price objectives for Myriad Genetics' stock. Their MYGN share price forecasts range from $23.00 to $32.00. On average, they expect the company's share price to reach $28.33 in the next year. This suggests a possible upside of 14.0% from the stock's current price.
View analysts price targets for MYGN
or view top-rated stocks among Wall Street analysts.

How have MYGN shares performed in 2022?

Myriad Genetics' stock was trading at $27.60 at the beginning of the year. Since then, MYGN stock has decreased by 9.9% and is now trading at $24.86.
View the best growth stocks for 2022 here
.

When is Myriad Genetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our MYGN earnings forecast
.

How were Myriad Genetics' earnings last quarter?

Myriad Genetics, Inc. (NASDAQ:MYGN) issued its earnings results on Thursday, August, 4th. The company reported $0.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.01 by $0.03. The company had revenue of $179.30 million for the quarter, compared to analyst estimates of $170.05 million. Myriad Genetics had a negative trailing twelve-month return on equity of 3.44% and a negative net margin of 2.62%. The company's revenue for the quarter was down 5.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.03 EPS.

What guidance has Myriad Genetics issued on next quarter's earnings?

Myriad Genetics updated its FY 2022 earnings guidance on Thursday, August, 18th. The company provided earnings per share guidance of -$0.10-0 for the period, compared to the consensus EPS estimate of $0.03. The company issued revenue guidance of $670.00 million-$700.00 million, compared to the consensus revenue estimate of $686.67 million.

What is Paul Diaz's approval rating as Myriad Genetics' CEO?

12 employees have rated Myriad Genetics Chief Executive Officer Paul Diaz on Glassdoor.com. Paul Diaz has an approval rating of 74% among the company's employees.

What other stocks do shareholders of Myriad Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Myriad Genetics investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Gilead Sciences (GILD), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), AT&T (T), Alibaba Group (BABA) and Kratos Defense & Security Solutions (KTOS).

What is Myriad Genetics' stock symbol?

Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN."

Who are Myriad Genetics' major shareholders?

Myriad Genetics' stock is owned by a variety of institutional and retail investors. Top institutional investors include State Street Corp (5.96%), Artisan Partners Limited Partnership (2.76%), Glenview Capital Management LLC (2.10%), Goldman Sachs Group Inc. (1.61%), Northern Trust Corp (1.53%) and Sei Investments Co. (1.46%). Insiders that own company stock include Alexander Ford, Daniel K Spiegelman, Dennis Langer, Jayne B Hart, Jerry S Lanchbury, Jerry S Lanchbury, John T Henderson, Nicole Lambert, Paul Parkinson, Richard Bryan Riggsbee, S Louise Phanstiel and Walter Phd Gilbert.
View institutional ownership trends
.

How do I buy shares of Myriad Genetics?

Shares of MYGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Myriad Genetics' stock price today?

One share of MYGN stock can currently be purchased for approximately $24.86.

How much money does Myriad Genetics make?

Myriad Genetics (NASDAQ:MYGN) has a market capitalization of $2.00 billion and generates $690.60 million in revenue each year. The company earns $-27,200,000.00 in net income (profit) each year or ($0.24) on an earnings per share basis.

How many employees does Myriad Genetics have?

The company employs 2,400 workers across the globe.

Does Myriad Genetics have any subsidiaries?
The following companies are subsidiares of Myriad Genetics: Assurex Health Inc., Assurex Health Ltd, Counsyl, Crescendo Bioscience, Crescendo Bioscience LLC, Javelin Pharmaceuticals, Myriad Autoimmune, Myriad Genetic Laboratories Inc., Myriad Genetics Australia PTY LTD, Myriad Genetics B.V., Myriad Genetics Canada Corp, Myriad Genetics Espana SL, Myriad Genetics GK, Myriad Genetics GmbH, Myriad Genetics LTD, Myriad Genetics S.r.l., Myriad Genetics SAS, Myriad GmbH, Myriad International GmbH, Myriad Neuroscience, Myriad Services GmbH, Myriad Women’s Health, Myriad Women’s Health Inc, NaturNorth Technologies, Privatklinik Dr. Robert Schindlbeck, Rules-Based Medicine, and Sividon Diagnostics.
Read More
When was Myriad Genetics founded?

Myriad Genetics was founded in 1991.

How can I contact Myriad Genetics?

Myriad Genetics' mailing address is 320 WAKARA WAY, SALT LAKE CITY UT, 84108. The official website for the company is www.myriad.com. The company can be reached via phone at (801) 584-3600, via email at sgleason@myriad.com, or via fax at 801-584-3640.

This page (NASDAQ:MYGN) was last updated on 8/19/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.